{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T23:20:47Z","timestamp":1711408847525},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,1,30]],"date-time":"2009-01-30T00:00:00Z","timestamp":1233273600000},"content-version":"vor","delay-in-days":2221,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:p>The effects of Y\u201027632, a Rho\u2010kinase inhibitor and BAY41\u20102272, a soluble guanylyl cyclase activator, on the tone and nitrergic responses of rabbit vaginal wall and clitoral corpus cavernosum were investigated. Y\u201027632 and BAY41\u20102272 (10 n<jats:sc>M<\/jats:sc>\u201310 \u03bc<jats:sc>M<\/jats:sc>) elicited concentration\u2010dependent relaxation of phenylephrine\u2010induced tone in both tissues. IC<jats:sub>50<\/jats:sub> values of Y\u201027632 for vaginal and clitoral tissues were 370\u00b130 n<jats:sc>M<\/jats:sc>, and 467\u00b114 n<jats:sc>M<\/jats:sc>, respectively. BAY41\u20102272 had IC<jats:sub>50<\/jats:sub> values of 478\u00b154 n<jats:sc>M<\/jats:sc> and 304\u00b138 n<jats:sc>M<\/jats:sc> respectively. The effect of the Y\u201027632 on the tissue tone was not affected by an inhibitor of nitric oxide synthase (<jats:sc>L<\/jats:sc>\u2010NAME; 500 \u03bc<jats:sc>M<\/jats:sc>). However, <jats:sc>L<\/jats:sc>\u2010NAME reduced the potency of BAY41\u20102272 in the clitoral corpus cavernosum but not in the vaginal wall. BAY41\u20102272 enhanced nitrergic relaxation responses only in the clitoral corpus cavernosum. Y\u201027632 had no effect on nitrergic relaxations in either tissue. These results demonstrate that Y\u201027632 and BAY41\u20102272 elicit relaxation of the rabbit vaginal wall and clitoral corpus cavernosum.<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2003) <jats:bold>138<\/jats:bold>, 287\u2013290. doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0705090\">10.1038\/sj.bjp.0705090<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0705090","type":"journal-article","created":{"date-parts":[[2003,2,8]],"date-time":"2003-02-08T17:22:02Z","timestamp":1044724922000},"page":"287-290","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Rho\u2010kinase inhibitor Y\u201027632 and the soluble guanylyl cyclase activator BAY41\u20102272 relax rabbit vaginal wall and clitoral corpus cavernosum"],"prefix":"10.1111","volume":"138","author":[{"given":"Selim","family":"Cellek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,30]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"543","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"AMERICAN PSYCHIATRIC ASSOCIATION","year":"2000"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702278"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/83258"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.54.6.962"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900648"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900596"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64009-8"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65142-7"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700982"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704124"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.2000.t01-2-00177.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/35065611"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/40187"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M204262200"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702921"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704481"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0705090","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0705090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0705090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:31:31Z","timestamp":1697218291000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0705090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1038\/sj.bjp.0705090"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0705090","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2009-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}